LA JOLLA, Calif., June 26 /PRNewswire-FirstCall/ -- Duska Therapeutics,
Inc. (OTC Bulletin Board: DSKA.OB) ("Duska" or the "Company") announced today
that its company information is available via Standard & Poor's Corporation
Records Listing Program. As part of the program, a full description of Duska
Therapeutics is published in the Daily News section of Standard Corporation
Records, a recognized securities manual for secondary trading in approximately
38 states under the Blue Sky Laws. Standard Corporation Records is available
in print, on CD-ROM, and via the Web at
http://www.netadvantage.standardandpoors.com as well as through numerous
electronic vendors.
The Duska Therapeutics corporate information now available through the
Records Listing Program includes an in-depth description of the Company's
business operations, share price, dividend history, shares outstanding,
company's financial position, earnings, and full income statement and balance
sheet.
Earlier this month Duska Therapeutics announced it has been granted an
exclusive worldwide license from Duke University and Johns Hopkins University
to develop and commercialize their rights to a portfolio of investigational
cardiovascular drugs designed to correct nitric oxide and redox disequilibrium
in the failing heart and cardiovascular system. The lead candidate is
expected to enter Phase II clinical trials later this year.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., in La Jolla, California, is a biotechnology
company focused on the development of medical products based on adenosine
triphosphate and nitric oxide. Duska owns or has exclusive licensing rights to
proprietary medical products that are in various stages of development for the
treatment and diagnosis of certain cardiac arrhythmias, treatment of heart
failure, treatment of chronic obstructive pulmonary disorder, and improvement
of sperm motility. For more information, visit
http://www.duskatherapeutics.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended that involve
risks and uncertainties that could cause actual events or results to differ
materially from the events or results described in the forward-looking
statements. The forward-looking statements are based on current expectations,
estimates and projections made by management. Duska intends for the
forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates," or variations of such words are
intended to identify such forward-looking statements. All statements in this
release regarding the future outlook related to Duska are forward-looking
statements such as the lead candidate is expected to enter Phase II clinical
trials later this year. The forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially from
those set forth or implied by any forward-looking statements. Additional
uncertainties and risks are described in Duska's most recently filed SEC
documents, such as its most recent annual report on Form 10-KSB, all quarterly
reports on Form 10-QSB and any current reports on Form 8-K filed since the
date of the last Form 10-KSB. Copies of these filings are available through
the SEC website at http://www.sec.gov. All forward-looking statements are
based upon information available to Duska on the date hereof. Duska undertakes
no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, other than
as required by law.
SOURCE Duska Therapeutics, Inc.
James S. Kuo, M.D., M.B.A., Chairman and CEO of Duska Therapeutics, Inc.,
+1-858-551-5700, Fax, +1-858-551-5704, kuoj@duskatherapeutics.com; or
Customers, Richard Albanese, +1-212-438-3647, Richard_albanese@sandp.com, or
Media relations, Michael Privitera, +1-212-438-6679,
michael_privitera@sandp.com, both of Standard & Poor's
